Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma

被引:16
作者
Hillengass, Jens [1 ]
Zechmann, Christian M. [2 ]
Nadler, Andreas [1 ]
Hose, Dirk
Cremer, Friedrich W. [3 ]
Jauch, Anna [3 ]
Heiss, Christiane [4 ,5 ]
Benner, Axel [4 ]
Ho, Anthony D. [1 ]
Bartram, Claus R.
Kauczor, Hans-Ulrich [2 ]
Delorme, Stefan [2 ]
Goldschmidt, Hartmut [1 ,5 ]
Moehler, Thomas M. [1 ]
机构
[1] Univ Heidelberg, Dept Hematol Oncol & Rheumatol, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Dept Radiol, D-6900 Heidelberg, Germany
[3] Univ Heidelberg, Inst Human Genet, D-69120 Heidelberg, Germany
[4] German Canc Res Ctr, Dept Biostat, D-6900 Heidelberg, Germany
[5] Natl Ctr Tumor Dis, Sect Multiple Myeloma, Heidelberg, Germany
关键词
multiple myeloma; monoclonal gammopathy of undetermined significance; dynamic contrast-enhanced magnetic resonance imaging; cytogenetics; in situ fluorescence hybridization;
D O I
10.1002/ijc.23455
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To identify genetic mechanisms controlling bone marrow microcirculation and angiogenesis in patients with plasma cell disease we simultaneously performed bone marrow dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and cytogenetics (iFISH) on CD138 purified plasma cells of MGUS (n = 31) and untreated multiple myeloma (MM) (n = 87) patients. The adverse cytogenetic abnormalities gain of 1q21, deletion 17p13 and deletion 13q14 significantly correlated with at least one DCE-MRI finding (aberrant "focal" microcirculation pattern, increase in median microcirculation parameter Amplitude A or exchange rate constant kep). We conclude that gain of 1q21, deletion 13q14 and deletion 17p13 trigger the angiogenic cascade in MM. Our findings will have important implications for the design, analysis and stratification for clinical studies of patients with MM in particular if compounds with antiangiogenic activity are used. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:2871 / 2875
页数:5
相关论文
共 50 条
  • [41] Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone
    Bochtler, Tilmann
    Hegenbart, Ute
    Kunz, Christina
    Benner, Axel
    Seckinger, Anja
    Dietrich, Sascha
    Granzow, Martin
    Neben, Kai
    Goldschmidt, Hartmut
    Ho, Anthony D.
    Hose, Dirk
    Jauch, Anna
    Schoenland, Stefan O.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2014, 21 (01): : 9 - 17
  • [42] Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study
    Chen, Haimin
    Zhou, Nian
    Shi, Haotian
    Yu, Wenjun
    Wu, Lixia
    Zhou, Fan
    HEMATOLOGY, 2023, 28 (01)
  • [43] Concomitant deletion of the short arm (Del 1p13.3) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
    Mohan, Meera
    Gong, Zimu
    Ashby, Timothy Cody
    Al Hadidi, Samer
    Thanendrarajan, Sharmilan
    Schinke, Carolina
    Alapat, Daisy
    Shaughnessy Jr, John D. D.
    Zhan, Fenghuang
    van Rhee, Frits
    Sawyer, Jeffery R.
    Tian, Erming
    Zangari, Maurizio
    CANCER, 2023, 129 (16) : 2491 - 2498
  • [44] Prognostic Value and Efficacy Evaluation of Novel Drugs for Multiple Myeloma Patients with 1q21 Amplification (Amp1q21) Only: A Systematic Review of Randomized Controlled Trials
    Chen, Liang
    Li, Zhendong
    Li, Shanshan
    Fu, Weijun
    Li, Rong
    JOURNAL OF CANCER, 2020, 11 (09): : 2639 - 2644
  • [45] Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
    Emiliano Barbieri
    Monica Maccaferri
    Giovanna Leonardi
    Francesca Giacobbi
    Giorgia Corradini
    Ivana Lagreca
    Patrizia Barozzi
    Leonardo Potenza
    Roberto Marasca
    Mario Luppi
    Annals of Hematology, 2022, 101 : 2777 - 2779
  • [46] Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience
    Barbieri, Emiliano
    Maccaferri, Monica
    Leonardi, Giovanna
    Giacobbi, Francesca
    Corradini, Giorgia
    Lagreca, Ivana
    Barozzi, Patrizia
    Potenza, Leonardo
    Marasca, Roberto
    Luppi, Mario
    ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2777 - 2779
  • [47] The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
    Gao, Lu
    Liu, Yang
    Li, Ye
    Feng, Lin
    Wang, Zheng
    Wen, Lei
    Wang, Fengrong
    Huang, Xiaojun
    Lu, Jin
    Lai, Yueyun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07) : 535 - 544
  • [48] Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications
    Kastritis, Efstathios
    Migkou, Magdalini
    Dalampira, Dimitra
    Gavriatopoulou, Maria
    Fotiou, Despina
    Roussou, Maria
    Kanellias, Nikolaos
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Theodorakakou, Foteini
    Sevastoudi, Aggeliki
    Eleutherakis-Papaiakovou, Evangelos
    Triantafyllou, Theodora
    Terpos, Evangelos
    Katodritou, Eirini
    Dimopoulos, Meletios A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (09) : 1142 - 1149
  • [49] Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma
    Wu, Ka Lung
    Beverloo, Berna
    Lokhorst, Henk M.
    Segeren, Christine M.
    van der Holt, Bronno
    Steijaert, Monique M.
    Westveer, Petra H.
    Poddighe, Pino J.
    Verhoef, Gregor E.
    Sonneveld, Pieter
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (04) : 615 - 623
  • [50] Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma
    Shaughnessy, J
    HEMATOLOGY, 2005, 10 : 117 - 126